- Home
- ANSC vs CMRX Comparison
ANSC vs CMRX Comparison
Compare ANSC & CMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANSC
- CMRX
- Stock Information
- Founded
- ANSC 2021
- CMRX 2000
- Country
- ANSC United States
- CMRX United States
- Employees
- ANSC N/A
- CMRX N/A
- Industry
- ANSC
- CMRX Biotechnology: Pharmaceutical Preparations
- Sector
- ANSC
- CMRX Health Care
- Exchange
- ANSC Nasdaq
- CMRX Nasdaq
- Market Cap
- ANSC 453.9M
- CMRX 394.1M
- IPO Year
- ANSC 2023
- CMRX 2013
- Fundamental
- Price
- ANSC $10.56
- CMRX $5.15
- Analyst Decision
- ANSC
- CMRX Strong Buy
- Analyst Count
- ANSC 0
- CMRX 2
- Target Price
- ANSC N/A
- CMRX $8.50
- AVG Volume (30 Days)
- ANSC 26.7K
- CMRX 1.7M
- Earning Date
- ANSC 01-01-0001
- CMRX 03-07-2025
- Dividend Yield
- ANSC N/A
- CMRX N/A
- EPS Growth
- ANSC N/A
- CMRX N/A
- EPS
- ANSC 0.21
- CMRX N/A
- Revenue
- ANSC N/A
- CMRX $159,000.00
- Revenue This Year
- ANSC N/A
- CMRX N/A
- Revenue Next Year
- ANSC N/A
- CMRX $1,690.28
- P/E Ratio
- ANSC $50.49
- CMRX N/A
- Revenue Growth
- ANSC N/A
- CMRX N/A
- 52 Week Low
- ANSC $10.12
- CMRX $0.75
- 52 Week High
- ANSC $10.60
- CMRX $5.53
- Technical
- Relative Strength Index (RSI)
- ANSC 62.76
- CMRX 76.25
- Support Level
- ANSC $10.54
- CMRX $3.94
- Resistance Level
- ANSC $10.54
- CMRX $5.53
- Average True Range (ATR)
- ANSC 0.01
- CMRX 0.30
- MACD
- ANSC 0.00
- CMRX 0.07
- Stochastic Oscillator
- ANSC 50.00
- CMRX 78.29
About ANSC Agriculture & Natural Solutions Acquisition Corporation
Agriculture & Natural Solutions Acquisition Corp is a blank check company.
About CMRX Chimerix Inc.
Chimerix Inc. is a biopharmaceutical company based in the United States that engages in the research, development, and commercialization of medicines. Its portfolio includes treatment for acute myeloid leukemia (or AML) and antiviral treatment for smallpox. The company generates revenue through revenue related to non-refundable upfront fees, royalties and milestone payments earned under license agreements, also by royalty revenue related to sales of TEMBEXA made by Emergent after the Asset Sale. The company operates only in one business segment namely pharmaceuticals.